Phospho-PARK2 (Ser101) Polyclonal Antibody, PE-Cy5.5 Conjugated
Product Specifications
Background
Parkinson's Disease, the second most common neurodegenerative disease after Alzheimer's Disease, is characterized by the loss of dopaminergic neurons and the presence of Lewy bodies (comprised of alpha synuclein and parkin inclusions) . Autosomal Recessive Juvenile Parkinsonism (AR-JP) is a recently described form of Parkinson's Disease that has been linked to a gene that codes for parkin. Parkin, a 52 kDa protein, has a suggested role in the ubiquitin/proteasome pathway for protein degradation. The amino terminus bears sequence homology to ubiquitin while functionally it acts as a RING type ubiquitin protein ligase (E3) that coordinates the transfer of ubiquitin to substrate proteins, thus targeting them for degradation by the proteasome.
Synonyms
PARK2phospho S101; AR JP; E3 ubiquitin protein ligase parkin; FRA6E; LPRS 2; LPRS2; PARK 2; PARK2; Parkinson disease autosomal recessive juvenile 2; Parkinson disease protein 2; Parkinson juvenile disease protein 2; PDJ; PRKN 2; PRKN; PRKN2; Ubiquitin E3 ligase PRKN.
Gene ID
5071
Modification Site
Ser101
Cellular Locus
Cytoplasm, Nucleus, Cell membrane
Host
Rabbit
Target
Phospho-PARK2 (Ser101)
Clonality
Polyclonal
Isotype
IgG
Conjugation
PE-Cy5.5
Source
KLH conjugated synthetic phosphopeptide derived from human PARK2 around the phosphorylation site of Ser101
Applications
WB
Purification
Purified by Protein A.
Excitation Emission
488nm/694nm
Concentration
1µg/µl
Dilution
WB (1:300-5000)
Buffer
Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Modification
Phosphorylation
Storage Conditions
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Gene ID URL
5071
Predicted Cross Reactivity
Human
More Discoveries
Explore Other Products
Browse additional items from our catalog
